Sep
29
Thu
Vernon Rice Memorial Holiday Turkey Program
Sep 29 – Nov 7 all-day
Vernon Rice Memorial Holiday Turkey Program

The INBT is pleased to participate for the fifth year with the Johns Hopkins community in the Vernon Rice Memorial Holiday Turkey Program, which supports the Baltimore community. For every $45 raised, a basket with a fresh turkey and vegetables from a local farm will be provided to a family in need. In the past five years, the INBT has provided 61 meals to families in need.

Learn more about Vernon Rice, the program, and how to donate.

Donations for the Thanksgiving holiday are due November 7, 2022. If you donate, email Gina at ginawadas@jhu.edu so we can continue tracking how many meals we supported.

 

 

Nov
3
Thu
Johns Hopkins Translational Immunoengineering Seminar: Stephen Miller, PhD
Nov 3 @ 12:00 pm – 1:00 pm

From Bench to Bedside: Translation of a Novel PLGA Nanoparticle Delivery System for Tolerogenic Therapy of Immune-Medicated Diseases

Seminar Take-Home Points

  • Tolerance induction using antigenencapsulating PLG nanoparticles (Ag-PLG) recapitulates how self-tolerance is induced and maintained in the hematopoietic system.
  • Ag-PLG uptake by splenic marginal zone and liver APCs via the MARCO scavenger receptor confers a tolerogenic phenotype and induces activation of CD4+Foxp3+, CD4+ Tr1, andCD8+CD122+ regulatory T cells which regulate effector T cell responses in a IL-10-dependentmanner.
  • Gliadin-encapsulating PLG nanoparticles have proven efficacious in a phase 2 double-blind, placebo-controlled trial in celiac disease patients significantly reducing the gliadin-specific T cell response and preventing intestinal damage upon gluten challenge.
  • Future disease indications under clinical development include multiple sclerosis (MS),neuromyelitis optica (NMO), and peanut allergy.

About the speaker
Dr. Stephen Miller is the Judy E. Gugenheim Research Professor Emeritus of MicrobiologyImmunology at Northwestern University Feinberg School of Medicine in Chicago. He received his Ph.D. in 1975 from the Pennsylvania State University and did postdoctoral training at the University of Colorado Health Sciences Center before joining the faculty at Northwestern in 1981 where he founded and served as Director of the Northwestern University Interdepartmental Immunobiology Center from 1992-2021. Dr. Miller is internationally recognized for his research on pathogenesis and regulation of autoimmune diseases. His current work is geared towards understanding the cellular and molecular mechanisms of T cell tolerance and translating the use of antigen-encapsulating biodegradable PLG nanoparticles for the treatment of other human immunemediated diseases including autoimmunity, allergy, protein and gene replacement therapy, and tissue/organ transplantation.

Zoom link.

 

 

Nov
11
Fri
Mucus Gels and Innate Lung Defense Seminar with Gregg Duncan @ Hodson Hall 210
Nov 11 @ 3:00 pm – 4:00 pm

All are welcome to a seminar with guest speaker Gregg Duncan and his presentation on, “Mucus Gels and Innate Lung Defense.” This is a hybrid event. Guests are welcome to come in-person in Hodson Hall 210 on the Johns Hopkins Homewood campus or by Zoom.

Zoom link and passcode: 530803

Mucus is a biological gel within the lung designed to behave like an “escalator” with the ability to capture potentially harmful inhaled materials (e.g. pathogens, particulates) and carry these materials via mucociliary clearance up to the throat to be swallowed and sterilized. A breakdown in lung mucus barrier function can lead to increased infections by respiratory viruses, such as influenza, rhinovirus, and coronaviruses, as they are not effectively removed from the airway. For these seasonal and emerging human viral pathogens, it is important to understand the mechanisms through which viral particles avoid adhesion to the mucus barrier and transport to the underlying epithelium to cause infection. To examine this, we measured influenza A virus and nanoparticle diffusion in mucus from human donors using high-speed fluorescent video microscopy and multiple particle tracking. Through these measurements, we can directly determine binding affinity and mode of adhesion for influenza A and other respiratory viruses in 3D human mucus matrices. MUC5B and MUC5AC are large, gel-forming mucins that assemble to form airway mucus gels. However due to the lack of appropriate models, it is not yet fully understood how MUC5B and MUC5AC individually or synergistically contribute to the biological function of mucus. To understand their unique roles in respiratory health, I will also discuss our studies on the rheological properties and transport function of mucus in human airway tissue cultures genetically engineered to secrete either MUC5B or MUC5AC. These bioengineered models provide key insights on how MUC5B and MUC5AC work in concert to enable host mucosal barrier function providing a highly valuable means to understand their roles in health and disease.

Speaker Bio: Gregg Duncan earned his Ph.D. in chemical engineering under the guidance of Michael Bevan at Johns Hopkins University. He then completed his postdoctoral training at Johns Hopkins School of Medicine in the Center for Nanomedicine directed by Justin Hanes. Dr. Duncan is currently an Assistant Professor in the Fischell Department of Bioengineering at the University of Maryland. Dr. Duncan leads the Respiratory Nano Bioengineering (RnB) lab, which aims to understand airway micro-physiology in health and disease to engineer new therapeutic strategies for obstructive lung diseases such as asthma, chronic obstructive pulmonary disease, and cystic fibrosis. Dr. Duncan is the recipient of several honors and awards including the Burroughs Wellcome Fund Career Award at the Scientific Interface, BMES Rita Schaffer Young Investigator Award, the CMBE Young Innovator Award, and the NSF CAREER Award

Nov
21
Mon
Advancing Biological Imaging and Sensing Using Quantum Technologies @ Maryland Hall 103
Nov 21 @ 2:00 pm – 3:00 pm

Advancing Biological Imaging and Sensing Using Quantum Technologies with Warwick Bowen.

Quantum technologies can exponentially accelerate computer simulations and detect signals that would be invisible to other technologies. This provides the potential for wide impact across the biosciences: better modelling of biochemical processes, and better imaging of biological systems. In this talk I will provide an overview of this potential, and how it could create a new field of quantum biotechnology. As an illustrative example, I will then introduce work in my laboratory that uses quantum correlated light to enhance bioimaging. In that work, we demonstrate for the first time that quantum correlations can be used to evade photochemical intrusion on the biological specimen, and therefore to observe biological structures that would be otherwise inaccessible. We achieve this in a coherent Raman microscope, providing chemically-specific information about the cell. Our results represents the first demonstration of absolute quantum advantage in biological microscopy, and we hope will open the door to a bright future for quantum bioimaging.

Professor Bowen’s research focuses on the implications of quantum science on precision measurement, and applications of quantum measurement in areas ranging from quantum condensed matter physics to the biosciences. He is the Director of the just announced Australian Research Council Centre of Excellence in Quantum Biotechnology. He is also a Fellow of the Australian Institute of Physics, Director of the University of Queensland Precision Technologies Translation Hub, and a Theme Leader of the Australian Centre for Engineered Quantum Systems. Prof Bowen’s research is supported by the Australian Research Council, the US Air Force Office of Scientific Research, Lockheed Martin, the US Army Research Office and the Australian Defence Science and Technology Group.

 

Dec
1
Thu
Probing and Attacking the Cancer Surfacome @ Virtual
Dec 1 @ 12:00 pm – 1:00 pm

Probing and Attacking the Cancer Surfacome with Jim Wells, PhD

The cell surface proteome(surfaceome)is a major hub for cellular communication and a primary source of drug targets, especially for biologics. My lab is interested in developing proteomic means to probe how the surfaceome changes in health and disease, especially cancer. Such changes involve alteration in protein expression and post-translational modifications such as proteolysis. I’ll describe new engineered tools we have built to probe the surfaceome changes that occur when oncogenes are expressed in isogenic cell lines to identify targets of interest. We then target proteins either upregulated, proteolyzed or both with recombinant antibodies derived by phage display to be used as validation tools and potential therapeutic leads

Jim received his BA from University of California at Berkeley, PhD from Washington State University (with Ralph Yount), and post-doc at Stanford (with George Stark), prior to joining Genentech, then Sunesis Pharmaceuticals, and finally UCSF. Wells’ group pioneered the engineering of proteins, antibodies, and small molecules that target catalytic, allosteric, and protein-protein interaction sites; and technologies including protein phage display, alanine-scanning, engineered proteases, bioconjugations, N-terminomics, disulfide “tethering”, and more recently an industrialized recombinant antibody production pipeline for the proteome. His team was integral to several protein products including Somavert for acromegaly, Avastin for cancer, Lifitegrast for dry eye disease, and engineered proteases sold by Pfizer, Genentech, Shire and Genencor, respectively. He is an elected member of the US National Academy of Science, American Association of Arts and Science, and the National Academy of Inventors.

This is a virtual event on Zoom. Click here to get the link.

Jan
3
Tue
Advances in Immunoengineering: Fundamentals and Cutting Edge Advances (2023) @ Virtual
Jan 3 @ 4:00 pm – Jan 19 @ 5:30 pm
Advances in Immunoengineering: Fundamentals and Cutting Edge Advances (2023) @ Virtual

The Advances in Immunoengineering: Fundamentals and Cutting Edge Advances workshop is hosted by Johns Hopkins Translational Immunoengineering. The workshop meets twice a week for three weeks and participants are eligible for CME credit. The workshop is also offered as a two-credit course to Johns Hopkins students

The immunoengineering field is transforming cancer, autoimmunity, regeneration, and transplantation treatments by combining the diverse and complex fields of engineering and immunology. There is a significant need to train engineers in immunology and immunologists in quantitative engineering techniques. Moreover, there is a need to bridge basic immunological discoveries with advances in clinical application. This workshop will review immune system fundamentals and components, engineering strategies to modulate the immune system, and clinical applications.

After attending this workshop, the learner will demonstrate the ability to:
– Review the fundamentals and recent discoveries in the function of the immune system.
– Identify engineering strategies to manipulate the immune system.
– Describe the clinical applications of immunoengineering.

The full schedule, speakers, topics, and registration information are available on JH-TIE’s website.